O Zmora1, Y Stark2, O Belotserkovsky2, M Reichert2, G A Kozloski2, N Wasserberg3, H Tulchinsky4, L Segev5, A J Senagore6, N Emanuel2. 1. Shamir Medical Center, Be'er Ya'akov, Israel. 2. PolyPid Ltd, Petach Tikvah, Israel. 3. Rabin Medical Center, Beilinson Campus, Petach Tikva, Israel. 4. Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel. 5. Sheba Medical Center, Tel-Hashomer, Ramat Gan, Israel. 6. PolyPid Ltd, Petach Tikvah, Israel. Anthony.S@polypid.com.
Abstract
BACKGROUND: Despite significant advances in infection control guidelines and practices, surgical site infections (SSIs) remain a substantial cause of morbidity, prolonged hospitalization, and mortality among patients having both elective and emergent surgeries. D-PLEX100 is a novel, antibiotic-eluting polymer-lipid matrix that supplies a high, local concentration of doxycycline for the prevention of superficial and deep SSIs. The aim of our study was to evaluate the safety and efficacy of D-PLEX in addition to standard of care (SOC) in preventing superficial and deep surgical site infections for patients undergoing elective colorectal surgery. METHODS: From October 10, 2018 to October 6, 2019, as part of a Phase 2 clinical trial, we randomly assigned 202 patients who had scheduled elective colorectal surgery to receive either standard of care SSI prophylaxis or D-PLEX100 in addition to standard of care. The primary objective was to assess the efficacy of D-PLEX100 in superficial and deep SSI reduction, as measured by the incidence of SSIs within 30 days, as adjudicated by both an individual assessor and a three-person endpoint adjudication committee, all of whom were blinded to study-group assignments. Safety was assessed by the stratification and incidence of treatment-emergent adverse events. RESULTS: One hundred and seventy-nine patients were evaluated in the per protocol population, 88 in the intervention arm [51 males, 37 females, median age (64.0 range: 19-92) years] and 91 in the control arm [57 males, 34 females, median age 64.5 (range: 21-88) years]. The SSI rate within 30 day post-index surgery revealed a 64% relative risk reduction in SSI rate in the D-PLEX100 plus standard of care (SOC) group [n = 7/88 (8%)] vs SOC alone [n = 20/91 (22%)]; p = 0.0115. There was no significant difference in treatment-emergent adverse events. CONCLUSIONS: D-PLEX100 application leads to a statistically significant reduction in superficial and deep surgical site infections in this colorectal clinical model without any associated increase in adverse events.
BACKGROUND: Despite significant advances in infection control guidelines and practices, surgical site infections (SSIs) remain a substantial cause of morbidity, prolonged hospitalization, and mortality among patients having both elective and emergent surgeries. D-PLEX100 is a novel, antibiotic-eluting polymer-lipid matrix that supplies a high, local concentration of doxycycline for the prevention of superficial and deep SSIs. The aim of our study was to evaluate the safety and efficacy of D-PLEX in addition to standard of care (SOC) in preventing superficial and deep surgical site infections for patients undergoing elective colorectal surgery. METHODS: From October 10, 2018 to October 6, 2019, as part of a Phase 2 clinical trial, we randomly assigned 202 patients who had scheduled elective colorectal surgery to receive either standard of care SSI prophylaxis or D-PLEX100 in addition to standard of care. The primary objective was to assess the efficacy of D-PLEX100 in superficial and deep SSI reduction, as measured by the incidence of SSIs within 30 days, as adjudicated by both an individual assessor and a three-person endpoint adjudication committee, all of whom were blinded to study-group assignments. Safety was assessed by the stratification and incidence of treatment-emergent adverse events. RESULTS: One hundred and seventy-nine patients were evaluated in the per protocol population, 88 in the intervention arm [51 males, 37 females, median age (64.0 range: 19-92) years] and 91 in the control arm [57 males, 34 females, median age 64.5 (range: 21-88) years]. The SSI rate within 30 day post-index surgery revealed a 64% relative risk reduction in SSI rate in the D-PLEX100 plus standard of care (SOC) group [n = 7/88 (8%)] vs SOC alone [n = 20/91 (22%)]; p = 0.0115. There was no significant difference in treatment-emergent adverse events. CONCLUSIONS: D-PLEX100 application leads to a statistically significant reduction in superficial and deep surgical site infections in this colorectal clinical model without any associated increase in adverse events.
Authors: Lindsey M Weiner-Lastinger; Sheila Abner; Jonathan R Edwards; Alexander J Kallen; Maria Karlsson; Shelley S Magill; Daniel Pollock; Isaac See; Minn M Soe; Maroya S Walters; Margaret A Dudeck Journal: Infect Control Hosp Epidemiol Date: 2019-11-26 Impact factor: 3.254
Authors: Ryan P Merkow; Mila H Ju; Jeanette W Chung; Bruce L Hall; Mark E Cohen; Mark V Williams; Thomas C Tsai; Clifford Y Ko; Karl Y Bilimoria Journal: JAMA Date: 2015-02-03 Impact factor: 56.272
Authors: Craig A Umscheid; Matthew D Mitchell; Jalpa A Doshi; Rajender Agarwal; Kendal Williams; Patrick J Brennan Journal: Infect Control Hosp Epidemiol Date: 2011-02 Impact factor: 3.254
Authors: Kristen A Ban; Joseph P Minei; Christine Laronga; Brian G Harbrecht; Eric H Jensen; Donald E Fry; Kamal M F Itani; E Patchen Dellinger; Clifford Y Ko; Therese M Duane Journal: J Am Coll Surg Date: 2016-11-30 Impact factor: 6.113
Authors: Laura Koskenvuo; Taru Lehtonen; Selja Koskensalo; Suvi Rasilainen; Kai Klintrup; Anu Ehrlich; Tarja Pinta; Tom Scheinin; Ville Sallinen Journal: Lancet Date: 2019-08-08 Impact factor: 79.321
Authors: Aaron L Klinger; Heather Green; Dominique J Monlezun; David Beck; Brian Kann; Herschel D Vargas; Charles Whitlow; David Margolin Journal: Ann Surg Date: 2019-04 Impact factor: 12.969